Beta Thalassemia | CHOP Research Institute
 

Beta Thalassemia

This clinical trial aims to test a new gene therapy in adults (18 to 35 years old) with beta thalassemia who require regular red cell transfusions.

Published on
Sep 9, 2022
In this Q&A, hematologist Dr. Kwiatkowski discusses the Food and Drug Administration approval of beti-cel (Zynteglo®), a gene therapy for beta thalassemia.
Published on
Sep 2, 2022
Learn about novel findings from our Children’s Hospital of Philadelphia researchers.
Published on
Jun 24, 2022
This week’s In the News features endocrinology research, news on gene therapy in blood disorders, CAR T-cell therapy, and more.
Published on
Apr 18, 2022
In the Emerging Innovators in Collaborative Research Program, up-and-coming researchers highlight their work.

This Phase 2 clinical research study is evaluating the safety and effectiveness of a once-daily oral investigational medicine that may improve anemia and reduce the need for red blood cell (RBC) transfusions among some patients who are chronically transfused.

Individuals with certain types of beta thalassemia that is treated with regular transfusions and who are up to 50 years old may be able to participate. A number of screening tests will be done to determine if subjects can participate.

This study assesses whether early chelation with deferiprone is effective at delaying the progression of iron overload in infants and young children.

Individuals with beta thalassemia that is treated with regular transfusions, and who are between the ages of 18 and 40 years old, may be able to participate.

Individuals with a certain type of beta thalassemia that is treated with regular transfusions, and who are 50 years old and younger, may be able to participate.